pharmaphorum
JUNE 1, 2021
Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside Japan to Heartseed’s HS-001 therapy based on heart muscle cells (cardiomyocytes) derived from human stem cells, and is due to start the phase 1/2 LAPiS trial in Japan later this year.
Pharma Times
JUNE 4, 2021
The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for VELPHORO Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Vifor Fresenius drug VELPHORO appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 1, 2021
The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drugâs effectiveness in preventing worsening of symptoms and hospitalization.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JUNE 2, 2021
In the latest edition of What HCPs Think , CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. The formation of blood clots is a necessary process in order for the body to repair damage caused by injury and to slow down bleeding. However, when blood clots form inappropriately, this limits blood flow through vessels and can pose a significant health risk.
Pharma Times
JUNE 2, 2021
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
JUNE 3, 2021
COVID-19 vaccination via Vaxxasâ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.
pharmaphorum
JUNE 4, 2021
AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it could extend the time for the cancer to return when used as adjuvant therapy. Giving Lynparza (olaparib) to women with BRCA-positive, HER2-negative breast cancer straight after chemotherapy and surgery to remove the tumour reduced the risk of recurrence, secondary cancers or death by 42% compared to placebo after 2.5 years of follow-up.
Pharma Times
JUNE 4, 2021
Officials warned that early evidence suggests there may be an increased risk of hospitalisation for Delta compared to the Alpha (Kent) strain
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for FERRIPROX Ferriprox is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are five patents protecting…. The post New patent for Chiesi drug FERRIPROX appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NY Times
MAY 30, 2021
I tried everything to treat my depression. Ketamine is the one thing that worked.
pharmaphorum
JUNE 4, 2021
The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. With sessions on both early and advanced stages of prostate cancer (Non-Metastatic Castrate-Resistant Prostate Cancer (nmCRPC) and Metastatic Castrate-Resistant Prostate Cancer (mCRPC) , this is a conversation not to mi
Pharma Times
JUNE 3, 2021
Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for VIBATIV Vibativ is a drug marketed by Cumberland Pharms and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent expiration for Cumberland Pharms drug VIBATIV appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 1, 2021
According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels.
pharmaphorum
JUNE 3, 2021
The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the world has changed over its history, NICE is coming to the end of a period of review and consultation on their processes and methods. Leela Barham takes stock. This article appears in our digital magazine Deep Dive: Market Access 2021.
Pharma Times
JUNE 2, 2021
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for GIMOTI Gimoti is a drug marketed by Evoke Pharma Inc and is included in one NDA. There are two patents protecting this drug. This drug…. The post New patent for Evoke Pharma drug GIMOTI appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 3, 2021
The pharma firm plans to use the StudyTeam platform to accelerate development, ease site burdens and improve patient matching for breast cancer studies.
pharmaphorum
JUNE 3, 2021
The FDA has approved a digital device developed by Cognoa that can be used to diagnose autism spectrum disorder (ASD), just a few weeks after it was filed for approval. Cognoa says the artificial intelligence (AI) based device is the first to be authorised by the US regulator that can help doctors diagnose autism in primary care, and will be launched “in the coming months” At the moment, autism can be difficult to diagnose as there are no medical markers to confirm its presence.
Pharma Times
JUNE 2, 2021
A WHO emergency use listing (EUL) is issued when a product meets international standards for safety, efficacy and manufacturing
Drug Patent Watch
JUNE 3, 2021
Annual Drug Patent Expirations for TYMLOS Tymlos is a drug marketed by Radius Health Inc and is included in one NDA. It is available from one supplier. There are three…. The post New patent for Radius Health drug TYMLOS appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
JUNE 1, 2021
The company’s application follows the move by Pfizer and BioNTech to seek full approval last month. The vaccines already have emergency use authorization in the United States.
pharmaphorum
JUNE 3, 2021
The UK government is talking to AstraZeneca about ordering additional doses of its COVID-19 vaccine that will target the beta variant of SARS-CoV-2 virus first identified in South Africa, according to Health Secretary Matt Hancock. The AZ/Oxford University vaccine and other shots from Pfizer/BioNTech and Moderna are known to have less efficacy against the beta variant – also known as B.1.351 – which is estimated to be around 50% more transmissible than earlier strains.
Pharma Times
JUNE 1, 2021
KHK4083 is an anti-OX40, fully human monoclonal antibody in development for the treatment of atopic dermatitis
Drug Patent Watch
JUNE 1, 2021
Annual Drug Patent Expirations for CARAC Carac is a drug marketed by Valeant Pharms North and is included in one NDA. It is available from three suppliers. There is one…. The post New patent expiration for Valeant Pharms drug CARAC appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 2, 2021
June 2021 marks the 40th anniversary of the publication of the first reported cases of AIDS in the US. A session at BIO Digital â featuring Dr. Anthony Fauci, Director of NIAID at the US NIH â will focus on four decades of innovation as well as the critical importance of collaboration and investment moving forward.
pharmaphorum
JUNE 2, 2021
The first batch of EU countries have started recognising the vaccination status of travellers using digital vaccine certificates as the bloc moves towards freeing up travel ahead of the summer period. Germany, Greece, Bulgaria, Czech Republic, Denmark, Croatia and Poland are the first to start using the scheme, which will allow people who have been fully vaccinated against COVID-19, tested negative recently, or recovered from the disease to travel without restriction within the EU.
Pharma Times
JUNE 3, 2021
IL-23 inhibitor helped patients achieve complete skin clearance and joint symptom improvement
Drug Patent Watch
JUNE 3, 2021
Want insights into the biggest revenue-changing events? ? Get Your Certificate Today By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay…. The post Get Your Certificate in Generic and Branded Drug Lifecycle Management appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 2, 2021
A robust research and innovation ecosystem makes Italy an attractive life sciences hotspot, according to a post from an Italian trade delegation at Bio Digital 2021.
pharmaphorum
JUNE 4, 2021
Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options live longer in a phase 3 trial. New data from the VISION study showed that 177Lu-PSMA-617 on top of standard care reduced the risk of death by 38% compared to standard care alone in men with PSMA-positive metastatic castration-resistant prostate cancer (CRPC) who had progressed after three or more anti-and
Pharma Times
JUNE 1, 2021
Phase II/III trial of the drug did not meet its futility criteria of the annualised rate change in total kidney volume (TKV)
Drug Patent Watch
JUNE 1, 2021
Annual Drug Patent Expirations for INGREZZA Ingrezza is a drug marketed by Neurocrine and is included in one NDA. It is available from one supplier. There are fifteen patents protecting…. The post New patent for Neurocrine drug INGREZZA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
JUNE 4, 2021
Today’s guest post comes from Nathan Mott, President of CoverMyMeds. Nathan discusses how technology can augment human expertise to help people access, afford, and adhere to their medications. To learn more, download CoverMyMeds’ new solutions overview: Technology Helps Drive Medication Access, Adherence and Affordability. Read on for Nathan’s insights.
Expert insights. Personalized for you.
138 
Let's personalize your content